RE:RE:ALL IN ALL looks like a decent REPORT!decent report, not to be lost in all this :
Study II utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433, activated by the TLC-3200, and is focused on the enrollment and treatment of approximately 100 BCG-Unresponsive NMIBC CIS patients in up to 20 clinical study sites located in Canada and the US.
Must remember these patients have failed the first line treatment, so are already presenting weakened bladders, urethras, etc . and are probably not in the greatest health to begin with. Now imagine if the trial was run as first treatment for newly diagnosed patients. CR would most likely be much higher , all IMHO.
Coop